EA202090882A1 - FUEL PROTEINS CONTAINING ENZYMES FOR ENZYME REPLACEMENT THERAPY - Google Patents

FUEL PROTEINS CONTAINING ENZYMES FOR ENZYME REPLACEMENT THERAPY

Info

Publication number
EA202090882A1
EA202090882A1 EA202090882A EA202090882A EA202090882A1 EA 202090882 A1 EA202090882 A1 EA 202090882A1 EA 202090882 A EA202090882 A EA 202090882A EA 202090882 A EA202090882 A EA 202090882A EA 202090882 A1 EA202090882 A1 EA 202090882A1
Authority
EA
Eurasian Patent Office
Prior art keywords
replacement therapy
enzyme replacement
proteins containing
fuel
containing enzymes
Prior art date
Application number
EA202090882A
Other languages
Russian (ru)
Inventor
Джузеппе Астарита
Марк С. Деннис
Дженнифер А. Гетц
Анастасия Генри
Михалис Кариолис
Катал Махон
Адам П. Силверман
Анкита Сривастава
Джули Аллман
Цзюньхуа Ван
Джой Ю Зучеро
Original Assignee
Денали Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Денали Терапьютикс Инк. filed Critical Денали Терапьютикс Инк.
Priority claimed from PCT/US2018/053747 external-priority patent/WO2019070577A1/en
Publication of EA202090882A1 publication Critical patent/EA202090882A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

В данном документе предложены слитые белки, содержащие ферменты для ферментной заместительной терапии и Fc-область, а также способы применения таких белков для лечения лизосомных болезней накопления. Также в данном документе предложены способы переноса агентов через гематоэнцефалический барьер.This document provides fusion proteins containing enzymes for enzyme replacement therapy and an Fc region, as well as methods of using such proteins for the treatment of lysosomal storage diseases. Also provided herein are methods for transferring agents across the blood-brain barrier.

EA202090882A 2018-08-22 2018-10-01 FUEL PROTEINS CONTAINING ENZYMES FOR ENZYME REPLACEMENT THERAPY EA202090882A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862721396P 2018-08-22 2018-08-22
PCT/US2018/053747 WO2019070577A1 (en) 2017-10-02 2018-10-01 Fusion proteins comprising enzyme replacement therapy enzymes

Publications (1)

Publication Number Publication Date
EA202090882A1 true EA202090882A1 (en) 2020-08-18

Family

ID=72235080

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090882A EA202090882A1 (en) 2018-08-22 2018-10-01 FUEL PROTEINS CONTAINING ENZYMES FOR ENZYME REPLACEMENT THERAPY

Country Status (1)

Country Link
EA (1) EA202090882A1 (en)

Similar Documents

Publication Publication Date Title
CO2020003128A2 (en) Fusion proteins comprising enzyme replacement therapy enzymes
EA201892561A1 (en) HYBRID PROTEINS GDF15 AND THEIR APPLICATION
PH12019550261A1 (en) Compositions and methods for internalizing enzymes
EA201891277A1 (en) COMPOSITIONS AND METHODS OF ENZYMALIZATION OF ENZYMES
PH12020551026A1 (en) Fusion protein comprising il-2 protein and cd80 protein, and use thereof
CL2020003255A1 (en) Fusion proteins comprising progranulin
MX2019006045A (en) Psma targeting trispecific proteins and methods of use.
EA201291138A1 (en) METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF VIOLATIONS CONNECTED WITH MATRIX MINERALIZATION
EA201590826A1 (en) WAYS OF CLEANING ARYLSULFATASE A
EA202092362A1 (en) VIRAL VECTORS FOR TARGETING EYE TISSUE
EA202091239A1 (en) FUSION PROTEIN BASED ON A THERAPEUTIC ENZYME WITH A NEW STRUCTURE AND ITS APPLICATION
EA202092419A1 (en) FUSION PROTEINS OF THE GROWTH DIFFERENTIATION FACTOR 15
EA201492177A1 (en) CLEANING IURONAT-2-SULFATASE
EA202090084A1 (en) NEW THERAPEUTIC ENZYME Fusion PROTEIN AND ITS APPLICATION
CO2022008648A2 (en) Progranulin variants
MX2018010196A (en) Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof.
EA202090372A1 (en) UNIVERSAL AVT CONNECTIONS AND THEIR APPLICATION
EA201591706A1 (en) SALTED FORMS (S) -CHINUCLIDIN-3-IL- (2- (2- (4-Fluoro-phenyl) TIAZOL-4-IL) PROPAN-2-IL) CARBAMATE
MX2021010061A (en) Cd80 extracellular domain-fc fusion proteins for treating pd-l1 negative tumors.
EA202091918A1 (en) CAR-T CELLS AND AUTOIMMUNE DISEASES
MX2020006586A (en) Methods for enhanced removal of impurities during protein a chromatography.
EA202090882A1 (en) FUEL PROTEINS CONTAINING ENZYMES FOR ENZYME REPLACEMENT THERAPY
BR112021013096A2 (en) TREATMENT OF SJÖGREN'S DISEASE WITH NUCLEASE FUSION PROTEINS
EA202192893A1 (en) ENVIRONMENT FOR CULTIVATION OF EUKARYOTIC CELLS
AR113339A1 (en) FUSION PROTEINS INCLUDING ENZYME REPLACEMENT THERAPY (ERT) ENZYMES AND A FC REGION